CIK 0001885522
NMRA Neumora Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Dec 27, 2024.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
3
with a Form 4 at this company
Signals
Open-market buys and sells at Neumora Therapeutics, Inc., scored.
| Score | Side | Insider | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 23Weak | sell 210b5-1 | Fust Matthew K director | $371k | 21,788 | -78% | - | |
| 15Weak | sell 210b5-1 | Lenz Robert A. Head of R&D | $208k | 13,823 | -4% | - |
Transactions
The last 17 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 27, 2024 | BERNS PAUL L director | GGift Common Stock | -133,097 | $0.00 | $0 | 7,685,069 | Dec 27, 2024 |
| Dec 27, 2024 | BERNS PAUL L director | GGift Common Stock | -133,097 | $0.00 | $0 | 7,551,972 | Dec 27, 2024 |
| Dec 27, 2024 | BERNS PAUL L director | GGift Common Stock | -133,097 | $0.00 | $0 | 7,418,875 | Dec 27, 2024 |
| Oct 17, 2024 | Fust Matthew K director | MOption exercise Common Stock10b5-1 | +3,783 | $8.32 | $31k | 23,883 | Oct 18, 2024 |
| Oct 17, 2024 | Fust Matthew K director | MOption exercise Common Stock10b5-1 | +1,800 | $8.79 | $16k | 25,683 | Oct 18, 2024 |
| Oct 17, 2024 | Fust Matthew K director | MOption exercise Common Stock10b5-1 | +2,156 | $2.52 | $5,433 | 27,839 | Oct 18, 2024 |
| Oct 17, 2024 | Fust Matthew K director | SOpen-market sale Common Stock10b5-1 | -7,739 | $17.01 | $132k | 20,100 | Oct 18, 2024 |
| Oct 18, 2024 | Fust Matthew K director | MOption exercise Common Stock10b5-1 | +6,205 | $8.79 | $55k | 26,305 | Oct 18, 2024 |
| Oct 18, 2024 | Fust Matthew K director | MOption exercise Common Stock10b5-1 | +7,844 | $2.52 | $20k | 34,149 | Oct 18, 2024 |
| Oct 18, 2024 | Fust Matthew K director | SOpen-market sale Common Stock10b5-1 | -14,049 | $17.03 | $239k | 20,100 | Oct 18, 2024 |
| Oct 17, 2024 | Fust Matthew K director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,783 | $0.00 | $0 | 0 | Oct 18, 2024 |
| Oct 17, 2024 | Fust Matthew K director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,800 | $0.00 | $0 | 6,205 | Oct 18, 2024 |
| Oct 17, 2024 | Fust Matthew K director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,156 | $0.00 | $0 | 93,430 | Oct 18, 2024 |
| Oct 18, 2024 | Fust Matthew K director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,205 | $0.00 | $0 | 0 | Oct 18, 2024 |
| Oct 18, 2024 | Fust Matthew K director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,844 | $0.00 | $0 | 85,586 | Oct 18, 2024 |
| Oct 9, 2024 | Lenz Robert A. Head of R&D | SOpen-market sale Common Stock10b5-1 | -5,563 | $15.01 | $84k | 322,966 | Oct 11, 2024 |
| Oct 10, 2024 | Lenz Robert A. Head of R&D | SOpen-market sale Common Stock10b5-1 | -8,260 | $15.09 | $125k | 314,706 | Oct 11, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- BERNS PAUL Ldirector
- Fust Matthew Kdirector
- Lenz Robert A.Head of R&D
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.